Manuel LÃ³pez-Cabrera

List of Publications by Year
in descending order

51 papers	3,784 citations	126858 33 h-index	168321 53 g-index
53 all docs	53 docs citations	53 times ranked	3403 citing authors

#	Article	IF	Citations
1	Peritoneal Dialysis and Epithelial-to-Mesenchymal Transition of Mesothelial Cells. New England Journal of Medicine, 2003, 348, 403-413.	13.9	694
2	Epithelial to Mesenchymal Transition and Peritoneal Membrane Failure in Peritoneal Dialysis Patients: Pathologic Significance and Potential Therapeutic Interventions. Journal of the American Society of Nephrology: JASN, 2007, 18, 2004-2013.	3.0	317
3	Mesenchymal Conversion of Mesothelial Cells as a Mechanism Responsible for High Solute Transport Rate in Peritoneal Dialysis: Role of Vascular Endothelial Growth Factor. American Journal of Kidney Diseases, 2005, 46, 938-948.	2.1	188
4	Blocking TGF-Î²1 Protects the Peritoneal Membrane from Dialysate-Induced Damage. Journal of the American Society of Nephrology: JASN, 2011, 22, 1682-1695.	3.0	146
5	Natural Plants Compounds as Modulators of Epithelial-to-Mesenchymal Transition. Frontiers in Pharmacology, 2019, 10, 715.	1.6	141
6	Carcinomaâ€associated fibroblasts derive from mesothelial cells via mesothelialâ€toâ€mesenchymal transition in peritoneal metastasis. Journal of Pathology, 2013, 231, 517-531.	2.1	134
7	Epithelial-to-mesenchymal transition of peritoneal mesothelial cells is regulated by an ERK/NF-ÎºB/Snail1 pathway. DMM Disease Models and Mechanisms, 2008, 1, 264-274.	1.2	104
8	The tetraspanin CD9 inhibits the proliferation and tumorigenicity of human colon carcinoma cells. International Journal of Cancer, 2007, 121, 2140-2152.	2.3	95
9	BMP-7 blocks mesenchymal conversion of mesothelial cells and prevents peritoneal damage induced by dialysis fluid exposure. Nephrology Dialysis Transplantation, 2010, 25, 1098-1108.	0.4	90
10	Epithelial-to-mesenchymal transition of the mesothelial cellâ€"its role in the response of the peritoneum to dialysis. Nephrology Dialysis Transplantation, 2006, 21, ii2-ii7.	0.4	89
11	miRâ€9â€5p suppresses proâ€fibrogenic transformation of fibroblasts and prevents organ fibrosis by targeting <scp>NOX</scp> 4 and <scp>TGFBR</scp> 2. EMBO Reports, 2015, 16, 1358-1377.	2.0	87
12	p38 maintains E-cadherin expression by modulating TAK1â€"NF-ÎºB during epithelial-to-mesenchymal transition. Journal of Cell Science, 2010, 123, 4321-4331.	1.2	84
13	Mesothelialâ€toâ€mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer. Journal of Pathology, 2017, 242, 140-151.	2.1	83
14	The hepatitis B virus HBx protein induces adherens junction disruption in a src-dependent manner. Oncogene, 2001, 20, 3323-3331.	2.6	82
15	Mesothelial-to-mesenchymal transition in the pathogenesis of post-surgical peritoneal adhesions. Journal of Pathology, 2016, 239, 48-59.	2.1	82
16	Caveolinâ€1 deficiency induces a <scp>MEK</scp>â€<scp>ERK</scp>1/2â€Snailâ€1â€dependent epithelialâ€"mesenchymal transition and fibrosis during peritoneal dialysis. EMBO Molecular Medicine, 2015, 7, 102-123.	3.3	79
17	Mesenchymal Conversion of Mesothelial Cells Is a Key Event in the Pathophysiology of the Peritoneum during Peritoneal Dialysis. Advances in Medicine, 2014, 2014, 1-17.	0.3	74
18	IL-17A is a novel player in dialysis-induced peritoneal damage. Kidney International, 2014, 86, 303-315.	2.6	74

#	ARTICLE	IF	CITATIONS
19	The Mesothelial Origin of Carcinoma Associated-Fibroblasts in Peritoneal Metastasis. Cancers, 2015, 7, 1994-2011.	1.7	72
20	Cyclooxygenase-2 Mediates Dialysate-Induced Alterations of the Peritoneal Membrane. Journal of the American Society of Nephrology: JASN, 2009, 20, 582-592.	3.0	65
21	PPAR-Î³ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage. Laboratory Investigation, 2010, 90, 1517-1532.	1.7	62
22	The dipeptide alanyl-glutamine ameliorates peritoneal fibrosis and attenuates IL-17 dependent pathways during peritoneal dialysis. Kidney International, 2016, 89, 625-635.	2.6	61
23	Paricalcitol Reduces Peritoneal Fibrosis in Mice through the Activation of Regulatory T Cells and Reduction in IL-17 Production. PLoS ONE, 2014, 9, e108477.	1.1	55
24	Biocompatible Dialysis Solutions Preserve Peritoneal Mesothelial Cell and Vessel Wall Integrity. A Case-Control Study on Human Biopsies. Peritoneal Dialysis International, 2016, 36, 129-134.	1.1	52
25	Mechanisms of Peritoneal Fibrosis: Focus on Immune Cellsâ€"Peritoneal Stroma Interactions. Frontiers in Immunology, 2021, 12, 607204.	2.2	47
26	Inhibition of Transforming Growth Factor-Activated Kinase 1 (TAK1) Blocks and Reverses Epithelial to Mesenchymal Transition of Mesothelial Cells. PLoS ONE, 2012, 7, e31492.	1.1	46
27	Epithelial to mesenchymal transition as a triggering factor of peritoneal membrane fibrosis and angiogenesis in peritoneal dialysis patients. Current Opinion in Investigational Drugs, 2005, 6, 262-8.	2.3	44
28	Hepatitis B virus X protein transactivates inducible nitric oxide synthase gene promoter through the proximal nuclear factor [kappa]B[ndash]binding site: Evidence that cytoplasmic location of X protein is essential for gene transactivation. Hepatology, 2001, 34, 1218-1224.	3.6	41
29	Caveolin1 and YAP drive mechanically induced mesothelial to mesenchymal transition and fibrosis. Cell Death and Disease, 2020, 11, 647.	2.7	39
30	Genomic reprograming analysis of the Mesothelial to Mesenchymal Transition identifies biomarkers in peritoneal dialysis patients. Scientific Reports, 2017, 7, 44941.	1.6	38
31	Ex vivo analysis of dialysis effluent-derived mesothelial cells as an approach to unveiling the mechanism of peritoneal membrane failure. Peritoneal Dialysis International, 2006, 26, 26-34.	1.1	37
32	Functional Relevance of the Switch of VEGF Receptors/Co-Receptors during Peritoneal Dialysis-Induced Mesothelial to Mesenchymal Transition. PLoS ONE, 2013, 8, e60776.	1.1	35
33	A Pathogenetic Role for Endothelin-1 in Peritoneal Dialysis-Associated Fibrosis. Journal of the American Society of Nephrology: JASN, 2015, 26, 173-182.	3.0	31
34	Immune-Regulatory Molecule CD69 Controls Peritoneal Fibrosis. Journal of the American Society of Nephrology: JASN, 2016, 27, 3561-3576.	3.0	31
35	Mesothelial-to-Mesenchymal Transition and Exosomes in Peritoneal Metastasis of Ovarian Cancer. International Journal of Molecular Sciences, 2021, 22, 11496.	1.8	31
36	miR-21 Promotes Fibrogenesis in Peritoneal Dialysis. American Journal of Pathology, 2017, 187, 1537-1550.	1.9	30

#	Article	IF	Citations
37	Chronic exposure of mouse peritoneum to peritoneal dialysis fluid: structural and functional alterations of the peritoneal membrane. Peritoneal Dialysis International, 2009, 29, 227-30.	1.1	28
38	Chronic Exposure of Mouse Peritoneum to Peritoneal Dialysis Fluid: Structural and Functional Alterations of the Peritoneal Membrane. Peritoneal Dialysis International, 2009, 29, 227-230.	1.1	25
39	Rapamycin Protects from Type-I Peritoneal Membrane Failure Inhibiting the Angiogenesis, Lymphangiogenesis, and Endo-MT. BioMed Research International, 2015, 2015, 1-15.	0.9	24
40	Mesothelial-to-Mesenchymal Transition Contributes to the Generation of Carcinoma-Associated Fibroblasts in Locally Advanced Primary Colorectal Carcinomas. Cancers, 2020, 12, 499.	1.7	22
41	Characterization of Epithelial-to-Mesenchymal Transition of Mesothelial Cells in a Mouse Model of Chronic Peritoneal Exposure to High Glucose Dialysate. Peritoneal Dialysis International, 2008, 28, 29-33.	1.1	21
42	Are the Mesothelial-to-Mesenchymal Transition, Sclerotic Peritonitis Syndromes, and Encapsulating Peritoneal Sclerosis Part of the Same Process?. International Journal of Nephrology, 2013, 2013, 1-7.	0.7	21
43	TWEAK Promotes Peritoneal Inflammation. PLoS ONE, 2014, 9, e90399.	1.1	21
44	Alanyl-Glutamine Restores Tight Junction Organization after Disruption by a Conventional Peritoneal Dialysis Fluid. Biomolecules, 2020, 10, 1178.	1.8	19
45	T Helper 17/Regulatory T Cell Balance and Experimental Models of Peritoneal Dialysis-Induced Damage. BioMed Research International, 2015, 2015, 1-9.	0.9	15
46	Mast Cell Quantification in Normal Peritoneum and During Peritoneal Dialysis Treatment. Archives of Pathology and Laboratory Medicine, 2006, 130, 1188-1192.	1.2	14
47	IL-17A as a Potential Therapeutic Target for Patients on Peritoneal Dialysis. Biomolecules, 2020, 10, 1361.	1.8	12
48	Tissue distribution of hyalinazing vasculopathy lesions in peritoneal dialysis patients. Pathology Research and Practice, 2008, 204, 563-567.	1.0	11
49	Cellular Integrin Î±5Î²1 and Exosomal ADAM17 Mediate the Binding and Uptake of Exosomes Produced by Colorectal Carcinoma Cells. International Journal of Molecular Sciences, 2021, 22, 9938.	1.8	11
50	Characterization of epithelial-to-mesenchymal transition of mesothelial cells in a mouse model of chronic peritoneal exposure to high glucose dialysate. Peritoneal Dialysis International, 2008, 28 Suppl 5, S29-33.	1.1	10
51	Increased miR-7641 Levels in Peritoneal Hyalinizing Vasculopathy in Long-Term Peritoneal Dialysis Patients. International Journal of Molecular Sciences, 2020, 21, 5824.	1.8	4